<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01064362</url>
  </required_header>
  <id_info>
    <org_study_id>113962</org_study_id>
    <secondary_id>EPI40612</secondary_id>
    <secondary_id>WEUSRTP4388</secondary_id>
    <nct_id>NCT01064362</nct_id>
  </id_info>
  <brief_title>Hemorrhage Risk Prescribed Arixtra</brief_title>
  <official_title>Risk of Hemorrhage in Patients Prescribed Arixtra Compared to LMWH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arixtra (fondaparinux sodium) was the first selective Factor Xa inhibitor to be marketed. As
      with all anticoagulants, an important adverse event associated with Arixtra use is
      haemorrhage. Previous studies using clinical trial and observational data show no difference
      in the risk of haemorrhage in patients treated with Arixtra compared to (low molecular weight
      heparins) LMWHs. This study will assess the risk of haemorrhage in major orthopaedic surgery
      patients (hip fracture surgery and/or hip/knee replacement surgery) treated with either
      Arixtra or LMWH for thromboprophylaxis and will provide additional observational data from a
      European country to strengthen the comprehensive review of haemorrhage and the post-marketing
      safety of Arixtra. All patients age 18 years and older with a primary discharge diagnosis for
      hip fracture surgery and/or a hospitalization for hip and/or knee replacement surgery from
      the PHARMO RLS database in the Netherlands are eligible for participation. For study
      inclusion patients must receive either Arixtra or LMWH as initial in-hospital
      thromboprophylactic agent and have at least three months in the PHARMO RLS database before
      cohort entry date. Patients with a history of hospitalization for haemorrhage, renal failure
      or liver failure in the past 3 months will be excluded. Descriptive statistics, including
      gender, age, length of treatment, co-morbidities, concomitant medications, and other
      covariates will be calculated.

      Data for this study were obtained from different registers in the PHARMO medical record
      linkage system (PHARMO RLS) in the Netherlands. The PHARMO medical record linkage system is a
      population-based patient-centric data tracking system that includes high quality and complete
      information of patient demographics, drug dispensing, and hospital morbidity records of
      approximately 2.3 million community-dwelling inhabitants of 48 geo-demographic areas in the
      Netherlands. The PHARMO registers are linked on a patient level and contain unprecedented
      accurate and complete information required for the study.

      The out patient database contains drug dispensing data in the U-Expo database are encoded
      according to standards based upon the Z-Index drug database (www.z-index.nl). Therefore, it
      is possible to identify and classify drug use in time, both on the basis of national and
      international classification schemes as well as on the basis of individual active ingredients
      and administration forms. Of each dispensed drug, the Anatomical Therapeutic Chemical (ATC)
      code, the dispensing date, the prescriber, the prescribed dosage regimen, the dispensed
      quantity, the cost and the estimated legend duration of use are available.

      The hospital pharmacy database comprises hospital pharmacy data collected in a growing number
      of non-academic hospitals in the Netherlands. Currently, data are collected on patient level
      for more than one million patients from a representative sample of non-academic hospital
      pharmacies scattered over the Netherlands. The hospital pharmacy database includes data on
      in-patient medication orders such as type of drug, dose, and time of administration and
      duration of use.

      The Dutch Medical Register (LMR) is the data source comprising all hospital admissions in the
      Netherlands (www.prismant.nl). These records include detailed information concerning the
      primary and secondary discharge diagnoses, diagnostic, surgical and treatment procedures,
      type and frequency of consultations with medical specialists and dates of hospital admission
      and discharge. All diagnoses are coded according to the International Classification of
      Diseases, 9th edition (ICD-9-CM). Currently, data until December 2008 are available.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were not recruited for nor enrolled in this study. This study is a retrospective
      observational study. Data from medical records or insurance claims databases are anonymised
      and used to develop a patient cohort. All diagnoses and treatment are recorded in the course
      of routine medical practice.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With the Indicated Types of Haemorrhages During Hospitalization or Follow-up for Major Orthopaedic Surgery of Lower Limbs (MOSLL)</measure>
    <time_frame>Follow-up continued until the date of first event, death, end of initial therapy, hospital discharge, end of follow-up in PHARMO RLS, or 60 days after discharge, whichever came first</time_frame>
    <description>Haemorrhages during MOSLL hospitalization or follow-up as identified by ICD-9-CM codes were measured. The PHARMO medical record linkage system (RLS), in the Netherlands, is a population-based patient-centric data tracking system that includes high quality/ complete information of patient demographics, drug dispensing, and hospital morbidity records of approximately 2.3 million inhabitants in the Netherlands.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Haemorrhages During Hospitalization for Major Orthopaedic Surgery of Lower Limbs (MOSLL)</measure>
    <time_frame>Follow-up continued until the date of first event, death, end of initial therapy, hospital discharge, end of follow-up in PHARMO RLS, or 60 days after discharge, whichever came first.</time_frame>
    <description>Haemorrhages during MOSLL hospitalization or follow-up as identified by ICD-9-CM codes were measured. The PHARMO medical record linkage system (RLS), in the Netherlands, is a population-based patient-centric data tracking system that includes high quality/ complete information of patient demographics, drug dispensing, and hospital morbidity records of approximately 2.3 million inhabitants in the Netherlands.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">13442</enrollment>
  <condition>Thrombosis, Venous</condition>
  <arm_group>
    <arm_group_label>Prophylaxis following major orthopedic surgery</arm_group_label>
    <description>Patients age 18 years and older in the PHARMO RLS database treated with either fondaparinux sodium or LMWH for thromboprophylaxis following hip fracture and/or hip/knee replacement surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fondaparinux sodium</intervention_name>
    <description>Fondaparinux sodium for thromboprophylaxis (ATC: B01AX05)</description>
    <arm_group_label>Prophylaxis following major orthopedic surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low molecular weight heparin (LMWH)</intervention_name>
    <description>LMWH including: dalteparin, nadroparin, enoxaparin or tinzaparin (ATC:B01AB (excluding B01AB01))</description>
    <arm_group_label>Prophylaxis following major orthopedic surgery</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients age 18 years and older with a primary discharge diagnosis of hip fracture surgery
        or hospitalization for hip replacement surgery or knee replacement surgery treated with
        either fondaparinux sodium or LMWH for thrombopropylaxis between January 2003 and September
        2008
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years and older; Treatment with either Arixtra or LMWH as initial in-hospital
             thromboprophylactic agent; At least three months history in the PHARMO RLS database
             before cohort entry date

        Exclusion Criteria:

          -  Hospitalization for haemorrhage, renal failure or liver failure in the 3 months before
             cohort entry date
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2010</study_first_submitted>
  <study_first_submitted_qc>February 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2010</study_first_posted>
  <results_first_submitted>January 25, 2011</results_first_submitted>
  <results_first_submitted_qc>January 25, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2011</results_first_posted>
  <last_update_submitted>April 23, 2015</last_update_submitted>
  <last_update_submitted_qc>April 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haemorrhage</keyword>
  <keyword>Thromboprophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fondaparinux</title>
          <description>All dosages of fondaparinux</description>
        </group>
        <group group_id="P2">
          <title>Low Molecular Weight Heparins (LMWHs)</title>
          <description>All dosages of LMWH, including Enoxaparin, Dalteparin, Nadroparin, and Tinzaparin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1559"/>
                <participants group_id="P2" count="11883"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1559"/>
                <participants group_id="P2" count="11883"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fondaparinux</title>
          <description>All dosages of fondaparinux</description>
        </group>
        <group group_id="B2">
          <title>Low Molecular Weight Heparins (LMWHs)</title>
          <description>All dosages of LMWH, including Enoxaparin, Dalteparin, Nadroparin, and Tinzaparin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1559"/>
            <count group_id="B2" value="11883"/>
            <count group_id="B3" value="13442"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Number of participants falling into the indicated age ranges</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18-64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="478"/>
                    <measurement group_id="B2" value="2962"/>
                    <measurement group_id="B3" value="3440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65-74 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="568"/>
                    <measurement group_id="B2" value="3433"/>
                    <measurement group_id="B3" value="4001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="513"/>
                    <measurement group_id="B2" value="5488"/>
                    <measurement group_id="B3" value="6001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1098"/>
                    <measurement group_id="B2" value="8280"/>
                    <measurement group_id="B3" value="9378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="461"/>
                    <measurement group_id="B2" value="3603"/>
                    <measurement group_id="B3" value="4064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with the indicated duration of their in-hospital stay</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0-7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="994"/>
                    <measurement group_id="B2" value="4826"/>
                    <measurement group_id="B3" value="5820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-10 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="428"/>
                    <measurement group_id="B2" value="2965"/>
                    <measurement group_id="B3" value="3393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11-14 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="1608"/>
                    <measurement group_id="B3" value="1683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=15 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="2484"/>
                    <measurement group_id="B3" value="2546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants hospitalized because of hip surgery and knee surgery</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Knee surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="414"/>
                    <measurement group_id="B2" value="3073"/>
                    <measurement group_id="B3" value="3487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hip surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1145"/>
                    <measurement group_id="B2" value="8810"/>
                    <measurement group_id="B3" value="9955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with the indicated duration of follow-up</title>
          <description>Follow-up includes time in the hospital.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1-14 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="790"/>
                    <measurement group_id="B2" value="4331"/>
                    <measurement group_id="B3" value="5121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15-28 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="477"/>
                    <measurement group_id="B2" value="1196"/>
                    <measurement group_id="B3" value="1673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>29-42 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="2232"/>
                    <measurement group_id="B3" value="2359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=43 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="4124"/>
                    <measurement group_id="B3" value="4289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with the indicated major risk factors or other key characteristics</title>
          <description>Non-specific non-steroidal anti-inflammatory drugs, ns-NSAIDs; PAU, prior antithrombotic use.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>PAU: Heparin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAU: LMWHs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAU: Vitamin K Antagonist (VKA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="351"/>
                    <measurement group_id="B3" value="381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAU: Fondaparinux</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAU: Multiple agents</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of platelet inhibitors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="293"/>
                    <measurement group_id="B2" value="2610"/>
                    <measurement group_id="B3" value="2903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of ns-NSAIDs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="395"/>
                    <measurement group_id="B2" value="2717"/>
                    <measurement group_id="B3" value="3112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization for hypercoagulable state</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization for cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization for thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="764"/>
                    <measurement group_id="B2" value="5645"/>
                    <measurement group_id="B3" value="6409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="378"/>
                    <measurement group_id="B2" value="2923"/>
                    <measurement group_id="B3" value="3301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization for cerebrovascular disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With the Indicated Types of Haemorrhages During Hospitalization or Follow-up for Major Orthopaedic Surgery of Lower Limbs (MOSLL)</title>
        <description>Haemorrhages during MOSLL hospitalization or follow-up as identified by ICD-9-CM codes were measured. The PHARMO medical record linkage system (RLS), in the Netherlands, is a population-based patient-centric data tracking system that includes high quality/ complete information of patient demographics, drug dispensing, and hospital morbidity records of approximately 2.3 million inhabitants in the Netherlands.</description>
        <time_frame>Follow-up continued until the date of first event, death, end of initial therapy, hospital discharge, end of follow-up in PHARMO RLS, or 60 days after discharge, whichever came first</time_frame>
        <population>From the PHARMO RLS, all patients &gt;=18 years of age with in-hospital pharmacy data, a primary discharge diagnosis for hip fracture and/or a hospitalization for MOSLL, and follow-up between January 2003 (introduction of Arixtra) and December 2008.</population>
        <group_list>
          <group group_id="O1">
            <title>Fondaparinux</title>
            <description>All dosages of fondaparinux</description>
          </group>
          <group group_id="O2">
            <title>Low Molecular Weight Heparins (LMWHs)</title>
            <description>All dosages of LMWH, including Enoxaparin, Dalteparin, Nadroparin, and Tinzaparin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Types of Haemorrhages During Hospitalization or Follow-up for Major Orthopaedic Surgery of Lower Limbs (MOSLL)</title>
          <description>Haemorrhages during MOSLL hospitalization or follow-up as identified by ICD-9-CM codes were measured. The PHARMO medical record linkage system (RLS), in the Netherlands, is a population-based patient-centric data tracking system that includes high quality/ complete information of patient demographics, drug dispensing, and hospital morbidity records of approximately 2.3 million inhabitants in the Netherlands.</description>
          <population>From the PHARMO RLS, all patients &gt;=18 years of age with in-hospital pharmacy data, a primary discharge diagnosis for hip fracture and/or a hospitalization for MOSLL, and follow-up between January 2003 (introduction of Arixtra) and December 2008.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1559"/>
                <count group_id="O2" value="11883"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bleeding or hematoma as complication of a surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epistaxis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal bleeds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemarthrosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intracranial bleeds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary tract bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Haemorrhages During Hospitalization for Major Orthopaedic Surgery of Lower Limbs (MOSLL)</title>
        <description>Haemorrhages during MOSLL hospitalization or follow-up as identified by ICD-9-CM codes were measured. The PHARMO medical record linkage system (RLS), in the Netherlands, is a population-based patient-centric data tracking system that includes high quality/ complete information of patient demographics, drug dispensing, and hospital morbidity records of approximately 2.3 million inhabitants in the Netherlands.</description>
        <time_frame>Follow-up continued until the date of first event, death, end of initial therapy, hospital discharge, end of follow-up in PHARMO RLS, or 60 days after discharge, whichever came first.</time_frame>
        <population>From the PHARMO RLS, all patients &gt;=18 years of age with in-hospital pharmacy data, a primary discharge diagnosis for hip fracture and/or a hospitalization for MOSLL, and follow-up between January 2003 (introduction of Arixtra) and December 2008.</population>
        <group_list>
          <group group_id="O1">
            <title>Fondaparinux</title>
            <description>All dosages of fondaparinux</description>
          </group>
          <group group_id="O2">
            <title>Low Molecular Weight Heparins (LMWHs)</title>
            <description>All dosages of LMWH, including Enoxaparin, Dalteparin, Nadroparin, and Tinzaparin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Haemorrhages During Hospitalization for Major Orthopaedic Surgery of Lower Limbs (MOSLL)</title>
          <description>Haemorrhages during MOSLL hospitalization or follow-up as identified by ICD-9-CM codes were measured. The PHARMO medical record linkage system (RLS), in the Netherlands, is a population-based patient-centric data tracking system that includes high quality/ complete information of patient demographics, drug dispensing, and hospital morbidity records of approximately 2.3 million inhabitants in the Netherlands.</description>
          <population>From the PHARMO RLS, all patients &gt;=18 years of age with in-hospital pharmacy data, a primary discharge diagnosis for hip fracture and/or a hospitalization for MOSLL, and follow-up between January 2003 (introduction of Arixtra) and December 2008.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1559"/>
                <count group_id="O2" value="11883"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bleeding or hematoma as complication of a surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epistaxis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>This is a retrospective study of pre-existing data; thus, no assessments for Serious or Non-serious Adverse Events were performed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fondaparinux</title>
          <description>All dosages of fondaparinux</description>
        </group>
        <group group_id="E2">
          <title>Low Molecular Weight Heparins (LMWHs)</title>
          <description>All dosages of LMWH, including Enoxaparin, Dalteparin, Nadroparin, and Tinzaparin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Differences among hospitals in the registration of events (not all events were captured), the presence of policlinical pharmacy, and different drug usage patterns in each hospital did not enable a valid comparison of the risk of haemorrhage.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

